CYP3A4-mediated carbamazepine (CBZ) metabolism: Formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile

Drug Metabolism and Disposition

Volumn 36, Issue 3, 2008, Pages 490-499

  Kang, Ping ^a,b   Liao, Mingxiang ^a   Wester, Michael R ^b   Leeder, J Steven ^c   Pearce, Robin E ^c   Correia, Maria Almira ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 3A4; ERYTHROMYCIN; GLUTATHIONE; N DEMETHYLASE; RECOMBINANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME KINETICS; ENZYME METABOLISM; ENZYME STRUCTURE; HUMAN; IN VIVO STUDY; INCUBATION TIME; MICHAELIS CONSTANT; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PURIFICATION; STOICHIOMETRY;

CARBAMAZEPINE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ERYTHROMYCIN; HUMANS; KINETICS; METHYLATION; MODELS, MOLECULAR; PROTEIN BINDING; RECOMBINANT PROTEINS; STEROID HYDROXYLASES; TESTOSTERONE;

EID: 40949102296     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016501     Document Type: Article

References (37)

1. Baer BR, Wienkers LC, and Rock DA (2007) Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964.
2. Bu HZ, Kang P, Deese AJ, Zhao P, and Pool WF (2005) Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab Dispos 33:1920-1924.
3. Denisov IG, Grinkova YV, Baas BJ, and Sligar SG (2006) The ferrous-dioxygen intermediate in human cytochrome P450 3A4. Substrate dependence of formation and decay kinetics. J Biol Chem 281:23313-23318.
4. Ekroos M and Sjogren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-136876.
5. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ, and Freer ST (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 2:317-324.
6. Gehlhaar D, Bouzida D, and Rejto PA (1999) Reduced dimensionality in ligand-protein structure prediction: covalent inhibitors of serine proteases and design of site-directed combinatorial libraries. ACS Symposium Series 719: Rational Drug Design. (Parrill AL and Reddy MR eds) pp 292-311, ACS Press, Washington, DC.
7. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci U S A 95:6636-6418.
8. Hart RG and Easton JD (1982) Carbamazepine and hematological monitoring. Ann Neurol 11:309-312.
9. He K, Bornheim LM, Falick AM, Maltby D, Yin H, Correia MA (1998) Identification of the heme-modified peptides from cumene hydroperoxide- inactivated cytochrome P450 3A4. Biochemistry 37:17448-17457.
10. Kalapos MP (2002) Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React Toxicol Rev 21:123-141.
11. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-5062.
12. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
13. Leeder JS (1998) Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39(suppl 7):S8-S16.
14. Leeder JS, Gaedigk A, Lu X, and Cook VA (1996) Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 49:234-243.
15. Licad-Coles E, He K, Yin H, and Correia MA (1997) Cytochrome P450 2C11: Escherichia coli expression, purification, functional characterization, and mechanism-based inactivation of the enzyme. Arch Biochem Biophys 338:35-42.
16. Lillibridge JH, Amore BM, Slattery JT, Kalhorn TF, Nelson SD, Finnell RH, and Bennett GD (1996) Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 24:509-514.
17. Madden S, Maggs JL, and Park BK (1996) Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 24:469-479.
18. Marrone TJ, Luty BA, and Rose PW (1999) Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: a virtual screening approach. Virtual screening: an alternative or complement to high throughput screening?, in Proceedings of the Workshop "New Approaches in Drug Design and Discovery," special topic "Virtual Screening;" 1999 March 15-18; Springer Netherlands, Schloâ Rauischholzhausen, Germany, pp 209-230.
19. Masubuchi Y, Nakano T, Ose A, and Horie T (2001) Differential selectivity in carbamazepineinduced inactivation of cytochrome P450 enzymes in rat and human liver. Arch Toxicol 75:538-543.
20. Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, Ohmori S, and Kitada M (2003) CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31:432-438.
21. Park BK, Coleman JW, and Kitteringham NR (1987) Drug disposition and drug hypersensitivity. Biochem Pharmacol 36:581-590.
22. Pearce RE, Vakkalagadda GR, and Leeder JS (2002) Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170-1179.
23. Pearce RE, Uetrecht JP, and Leeder JS (2005) Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 33:1819-1826.
24. Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, et al. (2001) Carbamazepine: a "blind" assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321-343.
25. Pirmohamed M, Kitteringham NR, Breckenridge AM, and Park BK (1992) The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol 44:2307-2314.
26. Romero Maldonado N, Sendra Tello J, Raboso Garcia-Baquero E, and Harto Castano A (2002) Anticonvulsant hypersensitivity syndrome with fatal outcome. Eur J Dermatol 12:503-505.
27. Schrag ML and Wienkers LC (2001) Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 391:49-55.
28. Shear NH, Spielberg SP, Cannon M, and Miller M (1988) Anticonvulsant hypersensitivity syndrome. In vitro risk assessment. J Clin Invest 82:1826-1832.
29. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-64554.
30. Ueng YF, Kuwabara T, Chun YJ, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
31. Wang RW, Newton DJ, Scheri TD, and Lu AY (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 25:502-507.
32. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, and Correia MA (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 37:12536-12545.
33. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
34. Wolkenstein P, Tan C, Lecoeur S, Wechsler J, Garcia-Martin N, Charue D, Bagot M, and Beaune P (1998) Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 113:39-50.
35. Xue L, Wang HF, Wang Q, Szklarz GD, Domanski TL, Halpert JR, Correia MA (2001) Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. Chem Res Toxicol 14:483-491.
36. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091- 38094.
37. Zangar RC, Davydov DR, and Verma S (2004) Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 199:316-331.